Production (Stage)
OS Therapies Incorporated
OSTX
$1.67
$0.042.45%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 76.06% | 70.80% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 68.54% | 21.70% | |||
| Operating Income | -68.54% | -21.70% | |||
| Income Before Tax | -29.61% | -4.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.61% | -4.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.61% | -4.03% | |||
| EBIT | -68.54% | -21.70% | |||
| EBITDA | -68.59% | -21.65% | |||
| EPS Basic | 20.04% | -26.09% | |||
| Normalized Basic EPS | -32.71% | 23.98% | |||
| EPS Diluted | 20.04% | -26.09% | |||
| Normalized Diluted EPS | -32.71% | 23.98% | |||
| Average Basic Shares Outstanding | -2.34% | 36.87% | |||
| Average Diluted Shares Outstanding | -2.34% | 36.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||